Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Bookmark and Share

AACR Annual Meeting 2022

8 - 13 Apr 2022
Louisiana, New Orleans, United States of America
Videos
News
Giving abatacept after checkpoint inhibitors can improve immunotherapy...
Dr Stephen Mok - The University of Texas MD Anderson Cancer Center, Houston, USA
Giving abatacept after checkpoint inhibitors can improve immunotherapy responses in melanoma ( Dr Stephen Mok - The University of Texas MD Anderson Cancer Center, Houston, USA )
19 May 2022
Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2...
Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA
Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100 ( Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
10 May 2022
Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for...
Prof Nicolas Girard - Institut Curie, Paris, France
Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for resectable NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )
10 May 2022
Natural killer cells complexed with a bispecific antibody may provide new...
Prof Yago Nieto - The University of Texas MD Anderson Cancer Center, Houston...
Natural killer cells complexed with a bispecific antibody may provide new treatment option for patients with advanced lymphoma ( Prof Yago Nieto - The University of Texas MD Anderson Cancer Center, Houston, USA )
26 Apr 2022
Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma...
Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid...
Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy ( Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid, Spain )
21 Apr 2022
Recurrent non-invasive breast tumours may not always be related to the primary...
Dr Tanjina Kader - University of Melbourne, Melbourne, Australia
Recurrent non-invasive breast tumours may not always be related to the primary lesion ( Dr Tanjina Kader - University of Melbourne, Melbourne, Australia )
19 Apr 2022
Safety and efficacy of olaparib plus metronomic cyclophosphamide and metformin...
Prof Benoit You - Hospices Civils de Lyon, Lyon, France
Safety and efficacy of olaparib plus metronomic cyclophosphamide and metformin in advanced/metastatic endometrial cancer ( Prof Benoit You - Hospices Civils de Lyon, Lyon, France )
14 Apr 2022
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid...
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )
14 Apr 2022
The adverse events atlas, towards a strategy to predict synergistic adverse...
Prof Bart Westerman - Amsterdam UMC, Amsterdam, Netherlands
The adverse events atlas, towards a strategy to predict synergistic adverse events of combination therapies ( Prof Bart Westerman - Amsterdam UMC, Amsterdam, Netherlands )
13 Apr 2022
Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid...
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
13 Apr 2022
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1...
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
13 Apr 2022
Novel COVID-19 vaccine for B-cell deficient patients
Prof Juliane Walz - University Hospital Tübingen, Tübingen, Germany
Novel COVID-19 vaccine for B-cell deficient patients ( Prof Juliane Walz - University Hospital Tübingen, Tübingen, Germany )
12 Apr 2022
Paediatric cancer patients in LMICS faced significantly higher mortality risk...
Dr Muhammed Elhadi - University of Tripoli, Tripoli, Libya
Paediatric cancer patients in LMICS faced significantly higher mortality risk during the COVID-19 pandemic ( Dr Muhammed Elhadi - University of Tripoli, Tripoli, Libya )
11 Apr 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation